<DOC>
	<DOC>NCT02759419</DOC>
	<brief_summary>Provide riociguat therapy to patients with Pulmonary Arterial Hypertension (PAH) originating from the Bayer-sponsored trials 12935 PATENT-2 or 16719 RESPITE who are currently or recently treated in these trials until lack of patient benefit, or commercial availability and reimbursement.</brief_summary>
	<brief_title>A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<criteria>Patients diagnosed with Pulmonary Arterial Hypertension (PAH) participating or having participated in the Bayersponsored studies 12935 or 16719, who have completed the main study phase and are still being treated with riociguat (either while still being on treatment with the respective study drug or by commercial means with Adempas) and who, in the opinion of the investigator, are expected to continue to have an overall positive benefit/risk from continuing treatment. Women and men of reproductive potential must agree to use adequate contraception when sexually active. This applies for the time period between signing of the informed consent form and 30 days after the last administration of study drug. Ongoing serious adverse event (SAE) from originating study that is assessed as related to riociguat Pregnant women or breastfeeding women. Any contraindication to Adempas treatment listed in the SmPC (Summary of Product Characteristics) Concomitant participation in another clinical study with the study drug. Patients with pulmonary Hypertension associated with idiopathic Interstitial pneumonia (PHIIP)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>